Top Markets
Coin of the day
CinCor Pharma, Inc. CinCor Pharma, Inc.

CinCor Pharma, Inc.

CINC
Rank in Stocks #11593
CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical... CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts.
Share Price
$29.06
Last synced: 2023-02-23
Market Cap
$682.73M
Change (1 day)
-0.48%
Change (1 year)
0.00%
Country
US
Trade CinCor Pharma, Inc. (CINC)

Category

Earnings for CinCor Pharma, Inc. (CINC)
Earnings in 2026 TTM: 0
According to CinCor Pharma, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for CinCor Pharma, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$-4.02B -
AU
$-3.09B -
US
- -
CH